Karyopharm Therapeutics Overview

Karyopharm Therapeutics EBIT

EBIT (Earnings Before Interest and Taxes) analysis for KPTI.

Quarterly EBIT

-$26.76M

↑ 19.53% YoY

As of Mar 31, 2026

Annual EBIT (TTM)

-$84.29M

↑ 21.54% YoY

Trailing 12 months ending Mar 31, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin